Paper Details

  1. Home
  2. Paper Details

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.

Author: AntoniadouA, DetsikaM, HatzakisA, KatsarolisI, PanagopoulosP, PapadopoulosA, ParaskevisD, PetrikkosG, ProtopapasK, SypsaV

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Atazanavir, an antiretroviral drug, can cause hyperbilirubinemia, a condition that can lead to jaundice. This study investigated the prevalence of the UGT1A1*28 variant, a genetic factor associated with hyperbilirubinemia, in HIV-infected individuals in Greece. The prevalence of the variant was high (58.2%) and was linked to higher maximum bilirubin levels in patients receiving atazanavir. While this study highlights the importance of genetic factors in drug response, further research is needed before recommending pharmacogenomics as a standard of care.
Paper Details　
Original Abstract of the Article :
Hyperbilirubinaemia with or without jaundice is one of the side effects of atazanavir boosted with low-dose ritonavir (ATV/rit) related to the drug plasma levels, as a result of its metabolism by UGT1A1 - uridine diphosphate-glucuronosyl transferase. Genotyping for UGT1A1*28 before initiation of ant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0956462414523259

データ提供：米国国立医学図書館（NLM）

Atazanavir and Hyperbilirubinemia: A Genetic Twist in the Desert

Atazanavir is a medication used to treat HIV infection. However, it can sometimes cause elevated bilirubin levels in the blood, leading to jaundice. This study investigates the genetic basis for this side effect, focusing on a specific gene called UGT1A1.

The UGT1A1 Gene: A Hidden Oasis in the Desert of Drug Metabolism

The researchers found that a specific variant of the UGT1A1 gene, called UGT1A1*28, was significantly more common in HIV-infected individuals who experienced hyperbilirubinemia while taking atazanavir. This suggests that genetic testing for this variant could be helpful in identifying individuals at higher risk of this side effect.

Personalized Medicine: A New Path Through the Desert

This study highlights the importance of personalized medicine, where treatment decisions are tailored to the individual's genetic makeup. By understanding the genetic factors that contribute to drug responses, doctors can make more informed choices about medication and minimize the risk of adverse effects.

Dr.Camel's Conclusion

This research delves into the genetic basis of atazanavir-induced hyperbilirubinemia, unveiling the role of the UGT1A1*28 variant. This study emphasizes the importance of personalized medicine in optimizing HIV treatment strategies and minimizing the risk of adverse effects. By understanding the genetic landscape of drug metabolism, we can pave a safer and more effective path through the desert of HIV treatment.

Date :
  1. Date Completed 2014-12-08
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24516079

DOI: Digital Object Identifier

10.1177/0956462414523259

Related Literature

Article Analysis
・Side Effects of atazanavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.